BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Vaccinex, Inc. VCNX
8 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$601,000
▲ 5.4% vs FY2023
EPS · FY24
$-8.88
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-3100.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 601,000.00
Revenue, FY2024 · full 8-year series below
Revenue
Net income
The company lost 3100 cents on every revenue dollar this year.
Per share
USD -8.88
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-3117.3%
Net margin-3100.5%
Return on assets-598.5%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+2.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.6%
+2.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.6M
total assets, end of FY2024
Total assetsUSD 2.6M
CashUSD 1.1M
Gross debtUSD 25,000.00
Net debtUSD -1.1M
Current ratio0.50×
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−8.88
−43.68
−98.05
−0.78
−1.54
−2.47
−5.65
−19.90
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
·
·
−267.3
·
·
·
·
·
Shares out B
0.00
0.00
0.00
0.03
0.02
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed